Content
Prescription weight loss that puts you first
Side-by-side medication summaries to compare approved uses, side effects, interactions, and more.
Content
Mounjaro
Phentermine
Mounjaro® (tirzepatide) is an injectable medication used to treat type 2 diabetes by improving blood sugar control and promoting weight loss. It functions by activating two receptors, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which enhance insulin secretion and slow gastric emptying. Mounjaro is administered once weekly, with dose adjustments made based on the patient's response. Common side effects include nausea, diarrhea, and decreased appetite. It should be used with caution in individuals with a history of thyroid cancer or multiple endocrine neoplasia syndrome type 2.
Phentermine is the active ingredient in brand-name medications including Adipex-P®, Fastin®, and Lomaira®. The information below is about brand name Adipex-P. According to the FDA, “Generic medicines use the same active ingredients as brand-name medicines and work the same way, so they have the same risks and benefits as the brand-name medicines.”
Adipex-P® (phentermine hydrochloride) is a prescription medication used as a short-term adjunct to weight loss in patients with obesity. It works as an appetite suppressant by stimulating the central nervous system, which increases heart rate and blood pressure while reducing hunger. Adipex-P is typically prescribed alongside a reduced-calorie diet and exercise regimen to enhance weight loss efforts. Common side effects include increased heart rate, dry mouth, insomnia, and nervousness. It is important to note that Adipex-P is intended for short-term use due to the potential for dependence and other adverse effects.
Prescription
Prescription
Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist
Sympathomimetic amine anorectic
Mounjaro (tirzepatide) is indicated:
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Adipex-P (phentermine hydrochloride) is indicated:
As a short-term adjunct (a few weeks) in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index greater than or equal to 30 kg/m2, or greater than or equal to 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia)
Typically taken as an injection once weekly
Comes in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL single-dose pens or single-dose vials
Typically taken orally once daily
Comes in 37.5 mg tablets
The most common adverse reactions, reported in ≥5% of patients treated with Mounjaro are:
Nausea
Diarrhea
Decreased appetite
Vomiting
Constipation
Indigestion
Abdominal pain
Adverse events have been reported in the cardiovascular, central nervous, gastrointestinal, allergic, and endocrine systems
Personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2
Known serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro
Drug interactions: Mounjaro delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications
History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension)
During or within 14 days following the administration of monoamine oxidase inhibitors
Hyperthyroidism
Glaucoma
Agitated states
History of drug abuse
Pregnancy
Nursing
Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines
Drug interactions: Monoamine oxidase inhibitors, alcohol, insulin and oral hypoglycemics, adrenergic neuron blocking drugs
Pancreatitis
Low blood sugar with concomitant use of insulin secretagogues or insulin
Hypersensitivity reactions
Acute kidney injury
Severe gastrointestinal disease
Diabetic retinopathy complications in patients with a history of diabetic retinopathy
Acute gallbladder disease
Pregnancy: Based on animal study, may cause fetal harm
Females of reproductive potential: Females using oral contraceptives should consider switching to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation
Coadministration with other drugs for weight loss is not recommended
Rare cases of primary pulmonary hypertension have been reported
Rare cases of serious regurgitant cardiac valvular disease have been reported
Tolerance to the anorectic effect usually develops within a few weeks
Adipex-P may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle
Risk of abuse and dependence
Concomitant alcohol use may result in an adverse drug reaction
Use caution in patients with even mild high blood pressure
A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients
Nursing mothers: Discontinue drug or nursing taking into consideration importance of drug to mother
WARNING: RISK OF THYROID C-CELL TUMORS
Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.
*This information is from the label for brand name Mounjaro. See the Full Prescribing Information for more complete information. Tirzepatide, the active ingredient in Mounjaro, is also the active ingredient in other brand-name medications, including Zepbound®, and this information may not be accurate for all medications that include the active ingredient tirzepatide.
*This information is from the label for brand name Adipex-P®. See the Full Prescribing Information for more complete information. Phentermine, the active ingredient in Adipex-P, is also the active ingredient in other brand-name medications, including Fastin® and Lomaira®, and this information may not be accurate for all medications that include the active ingredient phentermine.
The information provided here is NOT MEDICAL ADVICE and is for informational and educational purposes only. The drug comparison tool does not determine eligibility for medications or treatments provided via the Hims/Hers platform. Consultation with a healthcare provider is required to assess suitability for any medical treatment based on individual health and medical history. All product names and associated trademarks are the property of their respective owners.